title: Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer.
abstract: OBJECTIVE
  Tetraspanin CD151 is known to be involved in cancer invasion and metastasis, and its overexpression appears to be associated with a poor prognosis for various types of cancer. However, the expression status of CD151 and its prognostic impact in advanced gastric cancer (AGC) has not yet been clarified.
  
  
  METHODS
  Immunohistochemistry was used to investigate the expression of CD151, c-erbB2, and c-Met in 159 cases of AGC. The clinicopathological and prognostic significance of these biomarkers were then evaluated.
  
  
  RESULTS
  The overexpression of CD151 was observed in a subset of advanced gastric adenocarcinomas (25.8 %), and c-erbB2 and c-Met were overexpressed in 15.1 and 35.2 % of the cohort, respectively. CD151 overexpression was more frequently observed in tumors from younger patients (P = 0.028). There were close associations between CD151 and c-erbB2 overexpression (P = 0.033) and between c-erbB2 and c-Met overexpression (P = 0.001). CD151 overexpression was closely correlated with patient' overall survival (OS; P < 0.001) and disease-free survival (DFS; P < 0.001). Furthermore, the expression rate of CD151 seemed to increase gradually according to the depth of invasion (T stage) (χ(2) test for trend; P = 0.101), N stage (P = 0.238), and pathologic stage (P = 0.153), although trends were not statistically significant. In a multivariate analysis, CD151 overexpression was an independent prognostic factor predicting worse OS (P = 0.002) and DFS (P = 0.005), along with the T and N stage.
  
  
  CONCLUSIONS
  CD151 was found to be an independent prognostic marker for patients with AGC.
authors.affiliation: Department of Hematology/Oncology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Republic of Korea.
authors.forename: Byung Woog
authors.initials: BW
authors.lastname: Kang
authors.forename: Dakeun
authors.initials: D
authors.lastname: Lee
authors.forename: Ho Young
authors.initials: HY
authors.lastname: Chung
authors.forename: Jae Ho
authors.initials: JH
authors.lastname: Han
authors.forename: Young-Bae
authors.initials: YB
authors.lastname: Kim
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000096:biosynthesis; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D013505:Digestive System Surgical Procedures; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D010865:Pilot Projects; D011379:Prognosis; D020794:Receptor Protein-Tyrosine Kinases / Q000096:biosynthesis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D013274:Stomach Neoplasms / Q000201:enzymology / Q000276:immunology / Q000378:metabolism* / Q000628:therapy; D005641:Tegafur / Q000008:administration & dosage; D060185:Tetraspanin 24 / Q000096:biosynthesis*; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D002945:Cisplatin; D004338:Drug Combinations; D010094:Oxonic Acid; D020794:Receptor Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D005641:Tegafur; D060185:Tetraspanin 24; C554715:CD151 protein, human; C079198:S 1 (combination); C080835:RON protein